|
Yasmin / YAZ / Ocella Background & FDA Documents
Yasmin was originally developed by Berlex Laboratories, a U.S. affiliate of Schering AG, Germany. It was approved for use on May 11, 2001. Yasmin has 21 active pills and seven placebo pills. Ocella is the generic equivalent.
In 2006, the drug company, Bayer, acquired Berlex and its parent company and marketed a more recent version of Yasmin, called YAZ that has 24 active pills and four placebo pills. The YAZ (24-day) formulation is FDA approved as a method of birth control, as well as a treatment for premenstrual dysphoric disorder (PMDD) and acne.
Yasmin/YAZ/Ocella is the first type of birth control to contain a different kind of hormone, called drsp or drospirenone (pronounced dros-peer-eh-known). Yasmin contains 3 mg drospirenone and 30 mcg ethinylestradiol per tablet. YAZ contains 3 mg drospirenone and 20 mcg ethinylestradiol per tablet.
The following FDA documents relating to Yasmin and YAZ are available by clicking on the following links below:
If you, or someone you love, has suffered a serious injury or worse while on this drug, please call us immediately for a consultation. There is
no charge to discuss this matter and the call is toll free: 1-888-841-9623.
To return to the Yasmin / YAZ / Ocella home page click here.
|
